Grifols (GRFS) Competitors $9.14 +0.14 (+1.56%) Closing price 04:00 PM EasternExtended Trading$9.14 -0.01 (-0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMCShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Which has more risk and volatility, TEVA or GRFS? Teva Pharmaceutical Industries has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Do analysts recommend TEVA or GRFS? Teva Pharmaceutical Industries currently has a consensus price target of $24.13, indicating a potential upside of 41.33%. Grifols has a consensus price target of $10.30, indicating a potential upside of 12.69%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, TEVA or GRFS? Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.18-$1.64B-$1.15-14.84Grifols$7.81B0.81$169.80M$1.177.81 Do insiders and institutionals believe in TEVA or GRFS? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer TEVA or GRFS? In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than Grifols. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 1 mentions for Grifols. Grifols' average media sentiment score of 0.82 beat Teva Pharmaceutical Industries' score of 0.74 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is TEVA or GRFS more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-7.74% 45.44% 6.95% Grifols N/A N/A N/A SummaryTeva Pharmaceutical Industries beats Grifols on 12 of the 17 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.28B$2.42B$5.49B$8.94BDividend YieldN/A1.79%5.38%4.13%P/E Ratio7.818.9526.2119.90Price / Sales0.81663.84415.20165.00Price / Cash9.66154.3736.4957.06Price / Book0.674.548.055.38Net Income$169.80M$31.16M$3.15B$248.50M7 Day Performance7.40%0.16%1.93%2.99%1 Month Performance10.12%8.82%4.91%6.03%1 Year Performance40.18%2.56%35.87%20.40% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols4.1197 of 5 stars$9.14+1.6%$10.30+12.7%+43.3%$6.28B$7.81B7.8126,300Analyst DowngradeTEVATeva Pharmaceutical Industries4.0707 of 5 stars$16.96+0.1%$24.44+44.1%+2.0%$19.45B$16.54B-14.7536,830SMMTSummit Therapeutics2.6135 of 5 stars$20.39-0.8%$35.09+72.1%+160.4%$15.14B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.908 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8833 of 5 stars$20.68-2.3%$39.17+89.4%-16.5%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.7934 of 5 stars$15.31+0.5%$16.95+10.7%-1.0%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5535 of 5 stars$175.78-0.6%$220.67+25.5%+28.4%$10.75B$393.54M-27.991,017Positive NewsVTRSViatris3.0377 of 5 stars$8.85-0.2%$10.40+17.5%-13.3%$10.39B$14.74B-2.7932,000QGENQiagen3.7647 of 5 stars$46.72-0.1%$47.74+2.2%+23.2%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.3556 of 5 stars$25.67-0.9%$46.61+81.6%-75.3%$9.93B$3.14B-2.945,800Trending NewsOptions VolumeGap UpBPMCBlueprint Medicines1.5434 of 5 stars$128.40+0.2%$128.06-0.3%+17.5%$8.29B$508.82M-51.98640High Trading Volume Related Companies and Tools Related Companies TEVA Alternatives SMMT Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives MRNA Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
